BridgeBio Pharma announced FDA granted approval to Truseltiq for advanced Cholangiocarcinoma
The FDA granted accelerated approval to infigratinib for previously treated locally advanced or metastatic Cholangiocarcinoma harbors FGFR2 fusion or rearrangement. Infigratinib (Truseltiq; BridgeBio ...